Modality
Cell Therapy
MOA
MALT1i
Target
B7-H3
Pathway
Ferroptosis
PompeEpilepsySCLC
Development Pipeline
Preclinical
Sep 2025
→ Mar 2031
PreclinicalCurrent
NCT06413381
775 pts·Epilepsy
2025-09→2031-03·Recruiting
775 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-03-225.0y awayInterim· Epilepsy
Trial Timeline
Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
Preclinical
Recruit…
Catalysts
Interim
2031-03-22 · 5.0y away
Epilepsy
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06413381 | Preclinical | Epilepsy | Recruiting | 775 | MRD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 |